On June 7, 2022 Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, reported that compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS) (Press release, Prelude Therapeutics, JUN 7, 2022, View Source [SID1234615730]). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting at McCormick Place, Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET.
"For the first time, physicians have access to an enhanced method of identifying which patients may have a significant or minimal benefit from adjuvant endocrine therapy based on individual tumor biology," said Pat Whitworth, MD, FACS, ASCO (Free ASCO Whitepaper) Presenter and Breast Surgical Oncologist Director, Nashville Breast Center; Associate Professor, University of Tennessee; and Managing Partner TME. "The results are meaningful and support a more tailored treatment plan for our DCIS patients."
DCISionRT stratified patients as low risk, neither adjuvant ET nor radiation therapy (RT) resulted in reduced 10-year ipsilateral breast recurrence (IBR) (5.6% BCS+ET vs BCS alone). Patients in the elevated risk group, benefited from adjuvant ET as well as RT.
"We are excited to share this unique data demonstrating the expanded utility of DCISionRT to guide personalized treatment decisions for DCIS patients," says Dan Forche, President and CEO of PreludeDx. "As precision medicine becomes the new standard of care, we are committed to continuous innovation to improve healthcare outcomes for early-stage breast cancer patients, clinicians and the healthcare system."
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score that identifies a woman’s risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT’s intelligent reporting provides a woman’s recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.